Drug intelligence / Profile preview

mumps vaccine, live attenuated

Development stage: Unknown
Lead developer: AIM Vaccine Co.
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

This is a live attenuated mumps vaccine developed and marketed by **AIM Kanghuai** (a wholly owned subsidiary of **AIM Vaccine Corporation**). The vaccine contains live attenuated mumps virus as its active ingredient and works by stimulating the body to develop active immunity against the mumps virus. It is indicated for the prevention of epidemic parotitis (mumps) in individuals aged 8 months and older. AIM Vaccine obtained approval for the vaccine in October 2004 and received GMP certification for production in January 2005. The vaccine is currently approved and commercially available in China.

Other names: Live Attenuated Mumps Vaccinemumps vaccine (live attenuated)

Beyond the preview

Go deeper on mumps vaccine, live attenuated.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mumps vaccine, live attenuated.

Explore the full profile